Updated January 25, 2013.
Synvisc-One is a single injection viscosupplement approved in the United States for the treatment of knee osteoarthritis. Synvisc-One became FDA-approved on Feb. 26, 2009. It is manufactured and marketed by Genzyme Corp.
Synvisc - the original formula - was FDA-approved in 1997. It is administered as a series of three weekly 2 milliliter injections (for a total of 6 ml). Both Synvisc and Synvisc-One contain the same material (hylan G-F 20) as well as the same total treatment volume.
But, Synvisc-One delivers the 6 ml of hylan G-F 20 in a single injection.
Synvisc-One can be used for patients with knee osteoarthritis pain who have not been sufficiently helped by conservative non-drug treatments and simple analgesics like acetaminophen. Patients being treated with Synvisc-One can achieve up to 6 months pain relief.
Patients with a known previous serious reaction to hyaluronan, the active ingredient in Synvisc and related products, should not be treated with Synvisc-One. Patients with infection in or around the affected knee should not be injected. Patients who are allergic to bird proteins, feathers, or egg products or those with venous or lymphatic problems in the leg should be treated cautiously. Likewise, for patients with severe inflammation in the knee.
Common adverse events associated with Synvisc-One included mild to moderate arthralgia, arthritis, injection site pain, and joint effusion.
No serious adverse events were reported.
Drainage of excess joint fluid is recommended prior to injection with Synvisc-One. After injection with Synvisc-One, you should avoid strenuous activity, including prolonged weightbearing activities, for about 48 hours after treatment.
Sources:
FDA Approves Genzyme's Synvisc-One for Osteoarthritis of the Knee. Genzyme Press Release. February 26, 2009.
Synvisc-One is a single injection viscosupplement approved in the United States for the treatment of knee osteoarthritis. Synvisc-One became FDA-approved on Feb. 26, 2009. It is manufactured and marketed by Genzyme Corp.
Synvisc - the original formula - was FDA-approved in 1997. It is administered as a series of three weekly 2 milliliter injections (for a total of 6 ml). Both Synvisc and Synvisc-One contain the same material (hylan G-F 20) as well as the same total treatment volume.
But, Synvisc-One delivers the 6 ml of hylan G-F 20 in a single injection.
Synvisc-One as an Osteoarthritis Treatment
Synvisc-One can be used for patients with knee osteoarthritis pain who have not been sufficiently helped by conservative non-drug treatments and simple analgesics like acetaminophen. Patients being treated with Synvisc-One can achieve up to 6 months pain relief.
Warnings and Precautions for Synvisc-One
Patients with a known previous serious reaction to hyaluronan, the active ingredient in Synvisc and related products, should not be treated with Synvisc-One. Patients with infection in or around the affected knee should not be injected. Patients who are allergic to bird proteins, feathers, or egg products or those with venous or lymphatic problems in the leg should be treated cautiously. Likewise, for patients with severe inflammation in the knee.
Common adverse events associated with Synvisc-One included mild to moderate arthralgia, arthritis, injection site pain, and joint effusion.
No serious adverse events were reported.
Advice for Patients Treated With Synvisc-One
Drainage of excess joint fluid is recommended prior to injection with Synvisc-One. After injection with Synvisc-One, you should avoid strenuous activity, including prolonged weightbearing activities, for about 48 hours after treatment.
Sources:
FDA Approves Genzyme's Synvisc-One for Osteoarthritis of the Knee. Genzyme Press Release. February 26, 2009.